Business
Rodedawg Intl. Ind., Inc. (OTC: RWGI) Expands into Healthcare with Acquisition of Elixicure™ Pain Relief
Rodedawg Intl. Ind., Inc. (OTC: RWGI) Expands into Healthcare with Acquisition of Elixicure™ Pain Relief.
About this update from Rodedawg International Industries, Inc.
[{"type":"text","content":"Company Expands Product Offering, Distribution Channels, Manufacturing, and Revenue StreamsCOSTA MESA, CA / OTC PR WIRE / May 11th, 2023 / Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces its expansion into the healthcare industry with the purchase of Elixicure™ Pain Relief. Chris Swartz, CEO of Rodedawg states, “We are very proud to announce to our shareholders that Rodedawg has acquired Elixicure™ and all its assets. Our shareholders are benefitting from the roadmap of 6 years of healthcare marketing experience and the evolution of the Elixicure™ brand. The Elixicure™ team raised over 3 and ½ million dollars and we are acquiring not only physical production equipment but we are gaining years of research, finalized formulas, packaging, branding, brand awareness and established revenue producing sales channels. The acquisition includes manufacturing equipment, transportation and warehouse equipment, sales personnel and sales channels with growing revenue streams. In its first few years of operation the company expanded exponentially and generated close to 1 million in revenues within 3 years of its start. The product set is already embedded in regional sports culture and has been a great success in chiropractic and healthcare centers. Rodedawg personnel will be adding to the management team and we fully expect to see Elixicure™ generate over 3 million in its first year as a Rodedawg company. This acquisition gives Rodedawg an the entrance into the multi-billion dollar pain relief market.”Chris Swartz, CEO, adds, “According to Allied Market Research, the global topical pain relief market size was valued at $8.8 billion in 2019, and is projected to reach $12.2 billion by 2027 at a CAGR of 5.2% from 2020 to 2027. This is a massive market and this acquisition positions the company to expand into products and services generating revenue streams back to the Rodedawg enterprise. Until the SAFE Banking ACT and national legalization of cannabis, this acquisition allows Rodedawg to develop channels of distributions with marketing and sales of products in mainstream national markets. Additionally, we will also be informing our shareholders of our expanded sales and marketing plan for Elixicure™ and a wide range of health care products with multi-faceted distribution sales channels.”...